Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study

Cain, L; Lafrance, C; Morton, S; Latour, C; Girard, M; Tiberghien, P; de la Taille, V; Datta, SS; Virk, MS; Andrews, J; Yahalom, V; Pugliese, AM; Alba, R; Charlewood, R; Kirwan, S; Yokoyama, APH; Kutner, JM; Nogues, EA; Martinez i Llonch, N; Daly, J; Irving, DO; Schulze, TJ; Huisman, E; Le Poole, K; Stanworth, S

Journal article

Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study

Abstract:: Background: Whether granulocytes for transfusion are beneficial remains uncertain, although some evidence suggests that efficacy may be dose‐related. Granulocytes are mostly produced by apheresis procedure, but other means of production are increasingly used. Methods: Centers that produce and/or use granulocytes were recruited through the BEST Collaborative and completed a detailed survey of granulocyte manufacture, specifications, clinical use, operational considerations, and data collection initiatives. Results: Fifteen national, regional, and local producers and/or users of granulocytes were included. Granulocytes were produced from apheresis procedure (n = 10), pooled buffy coats (n = 2), single buffy coats (n = 4) or pooling of residual leukocyte units from whole blood processing (n = 1). The mean adult dose of granulocytes reported was 1.6 to 3.7 × 1010 for apheresis, and 1.8 to 2.2 × 1010 for pooled buffy coat granulocytes. For apheresis procedure donations, donor stimulation included steroids and/or granulocyte colony‐stimulating factor. Centers providing whole blood‐derived granulocytes reported shorter times from request to delivery than those using apheresis procedure products. Indications and product selection criteria were similar. The most frequently reported challenges with granulocytes were donor availability for apheresis procedure (n = 7), short shelf life (n = 5) and lack of evidence of efficacy (n = 5). The cost of one unit of apheresis procedure granulocytes ranged from 568 to 7500 PPP‐USD, and for one pooled buffy coat unit was from 2208 to 2822 PPP‐USD. Conclusions: We have highlighted differences in granulocyte production that are relevant for the design and interpretation of much needed international clinical studies.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Cain, L., Lafrance, C., Morton, S., Latour, C., Girard, M., Tiberghien, P., de la Taille, V., Datta, S. S., Virk, M. S., Andrews, J., Yahalom, V., Pugliese, A. M., Alba, R., Charlewood, R., Kirwan, S., Yokoyama, A. P. H., Kutner, J. M., Nogues, E. A., Martinez i Llonch, N., … Stanworth, S. (2025). Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study. Transfusion.

MLA Style

Cain, L., et al. “Differences in the Product Characteristics and Clinical Use of Granulocytes for Transfusion: The BEST Collaborative Study.” Transfusion, Wiley, 2025.

Chicago Style

Cain, L, C Lafrance, S Morton, C Latour, M Girard, P Tiberghien, V de la Taille, et al. 2025. “Differences in the Product Characteristics and Clinical Use of Granulocytes for Transfusion: The BEST Collaborative Study.” Transfusion.
Share
Print